Michigan-Based Cancer Drug Identification Company Intervention Insights Raises $7.2 Million
Intervention Insights is a Grand Rapids, Michigan based company that has raised $7.2 million to build and commercialize software that would help doctors identify the proper drugs to create specific types of cancer. Investors in this round include Farmington Hills, Michigan based private equity company Beringea, and Kentucky-based Chrysalis Ventures. The Hopen Life Sciences and Michigan Accelerator Fund I also participated in this round.
“It’s a really strong syndicate,” stated Beringea managing director Michael Gross. Gross and Chrysalis Ventures managing director Koleman Karleski, will be joining the board of directors at Intervention Insights. Intervention Insights was founded in 2009. The funding will be used to expand sales.